Figures
1. Swimmer plot showing the clinical course of each patient over time.
Each bar represents one patient treated with venetoclax, color-coded
based on diagnosis (AML, pink; B-ALL, green; MDS, blue). Dates of severe
infection, hematopoietic stem cell transplantation (HSCT), disease
progression, or death are depicted by symbols. Therapy combined with
venetoclax are shown on the left with a white box (hypomethylating
agent, HMA) or black box (chemotherapy). Response to therapy is depicted
in the second column to the left: circles are filled (complete response,
CR), partially filled (partial response, PR), empty (stable disease,
SD), or contain an “X” (PD, progressive disease)
2. One-year overall and progression-free survival for 13 patients
treated with venetoclax combination therapy